TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)?

被引：49
作者：
De Meulenaere A. [1 ]
Vermassen T. [1 ]
Aspeslagh S. [2 ]
Vandecasteele K. [3 ]
Rottey S. [1 ]
Ferdinande L. [4 ]
机构：
[1] Department of Medical Oncology, Ghent University Hospital, De Pintelaan 185, Ghent
[2] DITEP, Gustave Roussy Cancer Centre, rue Edouard-Vaillant 114, Villejuif
[3] Department of Radiation Oncology, Ghent University Hospital, De Pintelaan 185, Ghent
[4] Department of Pathology, Ghent University Hospital, De Pintelaan 185, Ghent
来源：
Head and Neck Pathology | 2017年 / 11卷 / 3期
关键词：
Biomarker; Prognosis; Squamous cell carcinoma of the head and neck; Tumor infiltrating lymphocytes;
D O I：
10.1007/s12105-016-0776-8
中图分类号：
学科分类号：
摘要：
The assessment of tumor infiltrating lymphocytes (TILs) has recently emerged as a prognostic biomarker in several solid tumors. Quantification and subtyping of TILs reflects the immune response in the tumor microenvironment, contributing to either tumoral immune attack or escape and thereby affecting outcome. Despite the growing evidence of its value as prognosticator, TILs analysis has not yet found its way to daily clinical practice. The aim of this review is to evaluate whether the current knowledge on TILs in head and neck cancer justifies its clinical implementation. Therefore, we summarize the data on TILs in squamous cell cancer of the head and neck with focus on the most important subsets (T lymphocytes and more specifically CD8+ cytotoxic T cells and FoxP3+ regulatory T cells) and site-specific characteristics such as Human Papilloma Virus infection. In addition, we discuss methodological problems and pitfalls that can account for discordant findings and that may hamper inclusion of TILs assessment in routine practice of pathologists and oncologists. © 2017, Springer Science+Business Media New York.
引用
收藏
页码：354 / 363
页数：9
相关论文
共 65 条
  • [11] Quezada S.A., Peggs K.S., Simpson T.R., Allison J.P., Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication, Immunol Rev, 241, 1, pp. 104-118, (2011)
  • [12] O'Sullivan T., Saddawi-Konefka R., Vermi W., Koebel C.M., Arthur C., White J.M., Et al., Cancer immunoediting by the innate immune system in the absence of adaptive immunity, J Exp Med, 209, 10, pp. 1869-1882, (2012)
  • [13] Palucka A.K., Coussens L.M., The Basis of Oncoimmunology, Cell, 164, 6, pp. 1233-1247, (2016)
  • [14] Parry R.V., Chemnitz J.M., Frauwirth K.A., Lanfranco A.R., Braunstein I., Kobayashi S.V., Et al., CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms, Mol Cell Biol, 25, 21, pp. 9543-9553, (2005)
  • [15] Campbell D.J., Koch M.A., Phenotypical and functional specialization of FOXP3 + regulatory T cells, Nature reviews Immunology, 11, 2, pp. 119-130, (2011)
  • [16] Vignali D.A., Collison L.W., Workman C.J., How regulatory T cells work, Nature reviews Immunology, 8, 7, pp. 523-532, (2008)
  • [17] Monu N.R., Frey A.B., Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship, Immunol Invest, 41, 6-7, pp. 595-613, (2012)
  • [18] Kumar V., Patel S., Tcyganov E., Gabrilovich D.I., The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment, Trends Immunol, 37, 3, pp. 208-220, (2016)
  • [19] Galon J., Mlecnik B., Bindea G., Angell H.K., Berger A., Lagorce C., Et al., Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours, J Pathol, 232, 2, pp. 199-209, (2014)
  • [20] Balermpas P., Rodel F., Rodel C., Krause M., Linge A., Lohaus F., Et al., CD8 + tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG), International journal of cancer Journal international du cancer, 138, 1, pp. 171-181, (2016)
1234567